Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenensis

Pathology International

Volumn 54, Issue 8, 2004, Pages 595-602

  Simooka, Hanako ^a   Oyama, Tetsunari ^a   Sano, Takaaki ^a   Horiguchi, Jun ^b   Nakajima, Takashi ^a,c  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

14 3 3 sigma; Breast carcinogenesis; Columnar cell hyperplasia with atypia; Immunohistochemistry; Precancerous lesions; Tumor suppressor

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN 14 3 3 SIGMA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DUCT; BREAST HYPERPLASIA; BREAST LESION; CARCINOMA IN SITU; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EXONUCLEASES; FEMALE; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 4344647941     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2004.01668.x     Document Type: Article

References (53)

1. Krishnamurthy S, Sneige N. Molecular and biologic markers of premalignant lesions of human breast. Adv Anat Pathol 2002; 9: 185-97.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
3. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-9.
4. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-5.
5. Niwa Y, Oyama T, Nakajima T. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 2000; 91: 519-26.
6. Miyamoto K, Fukutomi T, Asada K et al. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 2002; 32: 79-84.
7. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-71.
8. Ferguson AT, Evron E, Umbricht CB et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97: 6049-54.
9. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001; 20: 3348-53.
10. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160: 605-12.
11. Hermeking H, Lengauer C, Polyak K et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
12. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-20.
13. Yang J, Winkler K, Yoshida M, Kornbluth S. Maintenance of G2 arrest in the Xenopus oocyte: a role for 14-3-3-mediated inhibition of Cdc25 nuclear import. EMBO J 1999; 18: 2174-83.
14. Aprelikova O, Pace AJ, Fang B, Koller BH, Liu ET. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 2001; 276: 25 647-50.
15. Urano T, Saito T, Tsukui T et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002; 417: 871-5.
16. Prasad GL, Valverius EM, McDuffie E, Cooper HL. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 1992; 3: 507-13.
17. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X et al. Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 2001; 61: 76-80.
18. Nakajima T, Shimooka H, Weixa P et al. Immunohistochemical demonstration of 14-3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage. Pathol Int 2003; 53: 353-60.
19. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Sasano H. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Jpn J Cancer Res 2000; 91: 1169-76.
20. Ariga N, Suzuki T, Moriya T et al. Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res 2001; 92: 302-8.
21. Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989; 20: 723-5.
22. Page DL, Dupont WD. Histologic indicators of breast cancer risk. Bull Am Coll Surg 1991; 76: 16.
23. Kusama R, Fujimori M, Matsuyama I et al. Clinicopathological characteristics of atypical cystic duct (ACD) of the breast: assessment of ACD as a precancerous lesion. Pathol Int 2000; 50: 793-800.
24. Azzopardi JG. Problems in breast pathology. In: Bennington JL, ed. Major Problems in Pathology, Vol. 11. Philadelphia: Saunders, 1979; 193-203.
25. Oyama T, Maluf H, Koerner F. Atypical cystic lobules: an early stage in the formation of low-grade ductal carcinoma in situ. Virchows Arch 1999; 435: 413-21.
26. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ('clinging ductal carcinoma in situ'): a simulator of normal mammary epithelium. Cancer 2000; 88: 2072-81.
27. Koerner F, Oyama T, Maluf H. Morphological observations regarding the origins of atypical cystic lobules (low-grade clinging carcinoma of flat type). Virchows Arch 2001; 439: 523-30.
28. Akiyama F, Sakamoto G. Flat type of intraductal carcinoma. In: Koike M, Mukai K, Fukayama M, eds. Early Cancer and Borderline Lesion, Pathology and Clinical Medicine. Tokyo: Bunkodo, 2001; 19 (Suppl.): 195-9 (in Japanese).
29. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC, 2003.
30. Azzopardi JG, Chepick OF, Hartmann WH et al., eds. WHO. Histological Typing of Breast Tumors, 2nd edn. Berlin: Springer, 1981.
31. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992; 23: 1095-7.
32. Koerner FC. Evaluation and significance of ductal epithelial proliferations of the breast. In: Harris NL, Young RH, Mark EJ, eds. Current Concepts in Surgical Pathology. Boston: Massachusetts General Hospital and Harvard Medical School, 2000; 1-15.
33. Rosen PP. Columnar cell hyperplasia. In: Rosen PP, ed. Rosen's Breast Pathology, 2nd edn. Philadelphia: Lippincott-Williams & Wilkins, 2001; 215-22.
34. The Japanese Breast Cancer Society, eds. General Rules for Clinical and Pathological Recording of Breast Cancer, 14th edn. Tokyo: Kanehara, 2000.
35. Stirling JW, Chandler JA. The fine structure of ducts and sub-areolar ducts in the resting gland of the female breast. Virchows Arch A Pathol Anat Histol 1977; 373: 119-32.
36. Smith CA, Monaghan P, Neville AM. Basal clear cells of the normal human breast. Virchows Arch A Pathol Anat Histopathol 1984; 402: 319-29.
37. Zhang RR, Man YG, Vang R et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res 2003; 5: R151-6.
38. Wetzels RH, Kuijpers HJ, Lane EB et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991; 138: 751-63.
39. Thomson SD, Ali S, Pickles L et al. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast. Int J Cancer 2001; 91: 152-8.
40. Aitken A, Collinge DB, van Heusden BP et al. 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci 1992; 17: 498-501.
41. Chitemerere M, Andersen TI, Holm R, Karlsen F, Borresen AL, Nesland JM. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 1996; 41: 103-9.
42. Zhang GJ, Kimijima I, Abe R et al. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Clin Cancer Res 1997; 3: 2329-35.
43. Done SJ, Arneson NC, Ozcelik H, Redston M, Andrulis IL. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 1998; 58: 785-9.
44. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999; 188: 237-44.
45. Erenburg I, Schachter B, Mira y Lopez R, Ossowski L. Loss of an estrogen receptor isoform (ERαΔ3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol 1997; 11: 2004-15.
46. Kalogeraki A, Panayiotides J, Tamiolakis D et al. P53 expression in patients with malignant and benign breast diseases. Anticancer Res 2000; 20: 1801-5.
47. Kang JH, Kim SJ, Noh DY, Choe KJ, Lee ES, Kang HS. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. J Mol Med 2001; 79: 648-55.
48. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 2003; 36: 73-84.
49. Boecker W, Moll R, Dervan P et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002; 198: 458-67.
50. Ma XJ, Salunga R, Tuggle JT et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003; 100: 5974-9.
51. Purkis PE, Steel JB, Mackenzie IC, Nathrath WB, Leigh IM, Lane EB. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990; 97: 39-50.
52. Boecker W, Moll R, Poremba C et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002; 82: 737-46.
53. Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275: 23 106-12.